117 related articles for article (PubMed ID: 1442149)
1. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
3. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
5. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827
[TBL] [Abstract][Full Text] [Related]
7. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Moritaka T; Shibayama T; Tabata M; Segawa Y; Takigawa N
Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
[TBL] [Abstract][Full Text] [Related]
11. Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance.
Kiura K; Ohnoshi T; Tabata M; Shibayama T; Kimura I
Acta Med Okayama; 1993 Jun; 47(3):191-7. PubMed ID: 8104372
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
Hong WS; Jung HY; Yang SK; Kim HR; Min YI
Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
[TBL] [Abstract][Full Text] [Related]
13. In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells.
Miyamoto H
Acta Med Okayama; 1986 Apr; 40(2):75-81. PubMed ID: 3012966
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
Kubota T; Suto A; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Jpn J Cancer Res; 1990 Aug; 81(8):827-33. PubMed ID: 2144515
[TBL] [Abstract][Full Text] [Related]
15. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T
Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Jun; 46(3):203-12. PubMed ID: 1354408
[TBL] [Abstract][Full Text] [Related]
17. Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines.
Takagi T; Yazawa Y; Suzuki K; Yamauchi Y; Kano Y
Invest New Drugs; 1996; 14(4):357-63. PubMed ID: 9157070
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
Kimura I; Ohnoshi T; Hiraki S; Miyamoto H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):830-6. PubMed ID: 3032107
[TBL] [Abstract][Full Text] [Related]
20. [New anthracycline analogues in the treatment of lung cancer].
Ueoka H; Ohnoshi T; Kimura I
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2146-9. PubMed ID: 1332624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]